RxDoctor Payments Data

Jitendra Patel, MD

Geriatric Medicine · Brookings, ORNPI 1588668230

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 79 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $441 and has fallen 74.0% since, to $115 in 2025. Among geriatric medicine clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,649in general payments, 2019–2025

Across 79 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$327
  • Johnson & Johnson$324
  • GSK$207
  • AstraZeneca$189
  • Novartis$151
  • Novo Nordisk$138
  • plus $312 from 11 others

What the payments were for

  • Food & beverage$1,649100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,649 in reported general payments places this provider in the 95th percentile of 35 geriatric medicine providers in Oregon.

See all geriatric medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$122,932
Medicare patients
301
Services billed
1,241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide18$18,338
EliquisApixaban12$15,832
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$13,226
XareltoRivaroxaban12$10,880
Duloxetine Hcl22$4,105
Fluticasone Propionate HfaFluticasone Propionate11$2,634
Divalproex Sodium15$2,060
SynthroidLevothyroxine Sodium28$1,444
Potassium Chloride37$760
Mirtazapine22$753
Gabapentin20$711
Atorvastatin Calcium61$648
Omeprazole25$607
Metformin Hcl52$478
Tamsulosin Hcl22$388

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$327$18,33818 claims
GSKTrelegy Ellipta$207$13,22620 claims
Johnson & JohnsonXarelto$324$10,88012 claims
AbbVieSynthroid$93$1,44428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 35 geriatric medicine providers in Oregon.

Other geriatric medicine in Brookings

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →